Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $112.6 million.

  • NewAmsterdam Pharma Co N.V's Shares Outstanding (Weighted Average) rose 25.12% to $112.6 million in Q3 2025 from the same period last year, while for Jun 2023 it was $81.6 million, marking a year-over-year change of. This contributed to the annual value of $92.4 million for FY2024, which is 5.10% down from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's Shares Outstanding (Weighted Average) is $112.6 million, which was up 0.32% from $112.3 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Shares Outstanding (Weighted Average) ranged from a high of $112.6 million in Q3 2025 and a low of $77.7 million during Q4 2022.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $92.4 million (2024), whereas its average is $95.8 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Shares Outstanding (Weighted Average) grew by 25.32% in 2023, and later dropped by 7.53% in 2024.
  • Over the past 4 years, NewAmsterdam Pharma Co N.V's Shares Outstanding (Weighted Average) (Quarterly) stood at $77.7 million in 2022, then grew by 25.32% to $97.3 million in 2023, then decreased by 5.10% to $92.4 million in 2024, then increased by 25.12% to $112.6 million in 2025.
  • Its last three reported values are $112.6 million in Q3 2025, $112.3 million for Q2 2025, and $109.8 million during Q1 2025.